Twist Bioscience CEO sells 9,671 shares in plan
Twist Bioscience CEO Emily M. Leproust reported option-related trades in Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Twist Bioscience CEO Emily M. Leproust reported option-related trades in Common Stock. She exercised employee stock options to acquire 9,671 shares at an exercise price of $8.82 per share, then sold 9,671 shares in open‑market transactions at prices around $65–66 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions she directly owns 858,887 shares of Common Stock and retains employee stock options, including a grant tied to 64,950 underlying shares with a $67.85 exercise price.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,671 shares ($546K approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
9,671 shs ($631K)
Approx. gross sale proceeds
$631K
Approx. exercise cost
$85K
Approx. pre-tax spread
$546K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 8,061 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,061 | $8.82 | $71K |
| Sale | Common Stock | 7,910 | $65.275 | $516K |
| Sale | Common Stock | 151 | $66.00 | $10K |
| Exercise | Employee Stock Option (right to buy) | 1,610 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,610 | $8.82 | $14K |
| Sale | Common Stock | 1,610 | $65.01 | $105K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 355,427 contracts for 64,950 underlying shares (Direct);
Common Stock — 858,887 shares (Direct)
Footnotes (9)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
- F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.06 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.00 to $66.01 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F6. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F7. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F8. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
- F9. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Key Figures
Shares sold: 9,671 shares
Sale prices: $65.01–$66.00 per share
Options exercise price: $8.82 per share
+4 more
7 metrics
Shares sold
9,671 shares
Open-market Common Stock sales on April 21–22, 2026
Sale prices
$65.01–$66.00 per share
Reported transaction prices for Common Stock sales
Options exercise price
$8.82 per share
Exercise price for employee stock options converted into 9,671 shares
Shares after transactions
858,887 shares
Direct Common Stock ownership following reported trades
Remaining option grant
64,950 underlying shares
Employee stock option with $67.85 exercise price expiring August 31, 2030
Net share change
9,671 net shares sold
NetBuySellShares from transaction summary (net-sell direction)
Additional option exercise
8,061 shares
Common Stock acquired via option exercise on April 22, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average sales price, Employee Stock Option (right to buy), performance stock options, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.06 per share."
Employee Stock Option (right to buy) financial
"Employee Stock Option (right to buy)... underlying security title: Common Stock..."
performance stock options financial
"Represents performance stock options granted to the reporting person on September 1, 2020..."
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Twist Bioscience (TWST) report for CEO Emily Leproust?
Twist Bioscience reported that CEO Emily Leproust exercised options for 9,671 Common Stock shares at $8.82 and sold 9,671 shares in open‑market transactions around $65–66. These trades were disclosed as part of a routine Form 4 insider transaction report.
Did the Twist Bioscience (TWST) CEO exercise stock options in this Form 4 filing?
Yes. The CEO exercised employee stock options to acquire 9,671 Common Stock shares at an exercise price of $8.82 per share. Corresponding derivative entries show these employee stock options converting into Common Stock as part of the reported transactions on April 21 and April 22.
Were the Twist Bioscience (TWST) CEO’s stock sales under a Rule 10b5-1 plan?
Yes. A footnote states that the transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person. Such plans are pre‑arranged trading programs designed to systematically sell shares over time under predetermined conditions.
What stock options remain for the Twist Bioscience (TWST) CEO after the reported trades?
The derivative summary shows remaining employee stock options, including one with a $67.85 exercise price tied to 64,950 underlying Common Stock shares expiring on August 31, 2030. Other options with various exercise prices and expiration dates are also listed with underlying share amounts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates